CoChat
Sign Up
Cited by 79Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications

Open access
Laforce, Robert, Rabinovici, Gil D·2011·Alzheimer's Research & Therapy
DOI 10.1186/alzrt93PMC PMC3308020
Open this paper in CoChat — free accountOpen PDF

Abstract

In the past decade, positron emission tomography (PET) with carbon-11-labeled Pittsburgh Compound B (PIB) has revolutionized the neuroimaging of aging and dementia by enabling in vivo detection of amyloid plaques, a core pathologic feature of Alzheimer's disease (AD). Studies suggest that PIB-PET is sensitive for AD pathology, can distinguish AD from non-AD dementia (for example, frontotemporal lobar degeneration), and can help determine whether mild cognitive impairment is due to AD. Although the short half-life of the carbon-11 radiolabel has thus far limited the use of PIB to research, a second generation of tracers labeled with fluorine-18 has made it possible for amyloid PET to enter the clinical era. In the present review, we summarize the literature on amyloid imaging in a range of neurodegenerative conditions. We focus on potential clinical applications of amyloid PET and its role in the differential diagnosis of dementia. We suggest that amyloid imaging will be particularly useful in the evaluation of mildly affected, clinically atypical or early age-at-onset patients, and illustrate this with case vignettes from our practice. We emphasize that amyloid imaging should supplement (not replace) a detailed clinical evaluation. We caution against screening asymptomatic individuals, and discuss the limited positive predictive value in older populations. Finally, we review limitations and unresolved questions related to this exciting new technique.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/alzrt93

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Bergström M Savitcheva I Huang GF Estrada S Ausén B Debnath ML Barletta J Price JC Sandell J Lopresti BJ Wall A Koivisto P Antoni G Mathis CA Långström B Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 2004 55 306 319 10.1002/ana.20009 14991808 · DOI · Paper page
  2. Bacskai BJ Frosch MP Freeman SH Raymond SB Augustinack JC Johnson KA Irizarry MC Klunk WE Mathis CA Dekosky ST Greenberg SM Hyman BT Growdon JH Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch Neurol 2007 64 431 434 10.1001/archneur.64.3.431 17353389 · DOI
  3. Ikonomovic MD Klunk WE Abrahamson EE Mathis CA Price JC Tsopelas ND Lopresti BJ Ziolko S Bi W Paljug WR Debnath ML Hope CE Isanski BA Hamilton RL DeKosky ST Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 2008 131 1630 1645 10.1093/brain/awn016 18339640 PMC2408940 · DOI · Paper page
  4. Bacskai BJ Hickey GA Skoch J Kajdasz ST Wang Y Huang GF Mathis CA Klunk WE Hyman BT Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice Proc Natl Acad Sci USA 2003 100 12462 12467 10.1073/pnas.2034101100 14517353 PMC218780 · DOI
  5. Fodero-Tavoletti MT Smith DP McLean CA Adlard PA Barnham KJ Foster LE Leone L Perez K Cortes M Culvenor JG Li QX Laughton KM Rowe CC Masters CL Cappai R Villemagne VL In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies J Neurosci 2007 27 10365 10371 10.1523/JNEUROSCI.0630-07.2007 17898208 PMC6673163 · DOI
  6. Lockhart A Lamb JR Osredkar T Sue LI Joyce JN Ye L Libri V Leppert D Beach TG PIB is a non-specific imaging marker of A peptide-related cerebral amyloidosis Brain 2007 130 2607 2615 10.1093/brain/awm191 17698496 · DOI · Paper page
  7. Klunk WE Wang Y Huang GF Debnath ML Holt DP Shao L Hamilton RL Ikonomovic MD DeKosky ST Mathis CA The binding of 2-(4'-methylaminophenyl)benzothiazole to post-mortem brain homogenates is dominated by the amyloid component J Neurosci 2003 23 2086 2092 12657667 PMC6741999
  8. Jagust WJ Amyloid imaging: coming to a PET scanner near you Ann Neurol 2010 68 277 278 10.1002/ana.22144 20818786 · DOI
  9. Clark CM Schneider JA Bedell BJ Beach TG Bilker WB Mintun MA Pontecorvo MJ Hefti F Carpenter AP Flitter ML Krautkramer MJ Kung HF Coleman RE Doraiswamy PM Fleisher AS Sabbagh MN Sadowsky CH Reiman EP Zehntner SP Skovronsky DM Use of florbetapir-PET for imaging β-amyloid pathology JAMA 2011 305 275 283 10.1001/jama.2010.2008 21245183 PMC7041965 · DOI · Paper page
  10. Fleisher AS Chen K Liu X Roontiva A Thiyyagura P Ayutyanont N Joshi AD Clark CM Mintun MA Pontecorvo MJ Doraiswamy PM Johnson KA Skovronsky DM Reiman EM Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia Due to Alzheimer disease Arch Neurol 2011 in press 21747008
  11. Villemagne VL Ong K Mulligan RS Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias J Nucl Med 2011 52 1210 1217 10.2967/jnumed.111.089730 21764791 · DOI
  12. Wolk DA Grachev ID Buckley C Kazi H Grady MS Trojanowski JQ Hamilton RH Sherwin P McLain R Arnold SE Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology Arch Neurol 2011 in press PMC4532383 21747004
  13. Jack CR Jr Knopman DS Jagust WJ Shaw LM Aisen PS Weiner MW Petersen RC Trojanowski JQ Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09)70299-6 20083042 PMC2819840 · DOI · Paper page
  14. Small GW Kepe V Ercoli LM Siddarth P Bookheimer SY Miller KJ Lavretsky H Burggren AC Cole GM Vinters HV Thompson PM Huang SC Satyamurthy N Phelps ME Barrio JR PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 2006 355 2652 2663 10.1056/NEJMoa054625 17182990 · DOI
  15. Pike KE Savage G Villemagne VL Ng S Moss SA Maruff P Mathis CA Klunk WE Masters CL Rowe CC Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 2007 130 2837 2844 10.1093/brain/awm238 17928318 · DOI · Paper page
  16. Rowe CC Ellis KA Rimajova M Bourgeat P Pike KE Jones G Fripp J Tochon-Danguy H Morandeau L O'Keefe G Price R Raniga P Robins P Acosta O Lenzo N Szoeke C Salvado O Head R Martins R Masters CL Ames D Villemagne VL Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 2010 31 1275 1283 10.1016/j.neurobiolaging.2010.04.007 20472326 · DOI · Paper page
  17. Knopman DS Parisi JE Salviati A Floriach-Robert M Boeve BF Ivnik RJ Smith GE Dickson DW Johnson KA Petersen LE McDonald WC Braak H Petersen RC Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 2003 62 1087 1095 14656067
  18. Mintun MA Larossa GN Sheline YI Dence CS Lee SY Mach RH Klunk WE Mathis CA DeKosky ST Morris JC [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006 67 446 452 10.1212/01.wnl.0000228230.26044.a4 16894106 · DOI · Paper page
  19. Mosconi L Rinne JO Tsui WH Berti V Li Y Wang H Murray J Scheinin N Någren K Williams S Glodzik L De Santi S Vallabhajosula S de Leon MJ Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer's Proc Natl Acad Sci USA 2010 107 5949 5954 10.1073/pnas.0914141107 20231448 PMC2851906 · DOI · Paper page
  20. Vandenberghe R Van Laere K Ivanoiu A Salmon E Bastin C Triau E Hasselbalch S Law I Andersen A Korner A Minthon L Garraux G Nelissen N Bormans G Buckley C Owenius R Thurfj ell L Farrar G Brooks DJ 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 2010 68 319 329 10.1002/ana.22068 20687209 · DOI
  21. Mormino EC Kluth JT Madison CM Rabinovici GD Baker SL Miller BL Koeppe RA Mathis CA Weiner MW Jagust WJ Episodic memory loss is related to hippocampal mediated β-amyloid deposition in elderly subjects Brain 2009 132 1310 1323 10.1093/brain/awn320 19042931 PMC2677792 · DOI · Paper page
  22. Jack CR Jr Lowe VJ Senjem ML Weigand SD Kemp BJ Shiung MM Knopman DS Boeve BF Klunk WE Mathis CA Petersen RC 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 2008 131 665 680 10.1093/brain/awm336 18263627 PMC2730157 · DOI · Paper page
  23. Dickerson BC Bakkour A Salat DH Feczko E Pacheco J Greve DN Grodstein F Wright CI Blacker D Rosas HD Sperling RA Atri A Growdon JH Hyman BT Morris JC Fischl B Buckner RL The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals Cereb Cortex 2009 19 497 510 10.1093/cercor/bhn113 18632739 PMC2638813 · DOI · Paper page
  24. Hedden T Van Dijk KR Becker JA Mehta A Sperling RA Johnson KA Buckner RL Disruption of functional connectivity in clinically normal older adults harboring amyloid burden J Neurosci 2009 29 12686 12694 10.1523/JNEUROSCI.3189-09.2009 19812343 PMC2808119 · DOI · Paper page
  25. Mormino EC Smiljic A Hayenga AO Onami SH Greicius MD Rabinovici GD Janabi M Baker SL Yen IV Madison CM Miller BL Jagust WJ Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging Cereb Cortex 2011 21 2399 2407 10.1093/cercor/bhr025 21383234 PMC3169663 · DOI
  26. Resnick SM Sojkova J Zhou Y An Y Ye W Holt DP Dannals RF Mathis CA Klunk WE Ferrucci L Kraut MA Wong DF Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB Neurology 2010 74 807 815 10.1212/WNL.0b013e3181d3e3e9 20147655 PMC2839197 · DOI · Paper page
  27. Villemagne VL Pike KE Darby D Maruff P Savage G Ng S Ackermann U Cowie TF Currie J Chan SG Jones G Tochon-Danguy H O'Keefe G Masters CL Rowe CC Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 2008 46 1688 1697 10.1016/j.neuropsychologia.2008.02.008 18343463 · DOI
  28. Storandt M Mintun MA Head D Morris JC Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh Compound B: cognitive decline associated with Aβ deposition Arch Neurol 2009 66 1476 1481 10.1001/archneurol.2009.272 20008651 PMC2796577 · DOI
  29. Sperling RA Jack CR Jr Black SE Frosch MP Greenberg SM Hyman BT Scheltens P Carrillo MC Thies W Bednar MM Black RS Brashear HR Grundman M Siemers ER Feldman HH Schindler RJ Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 2011 7 367 385 10.1016/j.jalz.2011.05.2351 21784348 PMC3693547 · DOI · Paper page
  30. Hyman BT Amyloid-dependent and amyloid-independent stages of Alzheimer disease Arch Neurol 2011 68 1062 1064 10.1001/archneurol.2011.70 21482918 · DOI
  31. Pontecorvo MJ Mintun MA PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease Alzheimer's Res Ther 2011 3 11 10.1186/alzrt70 21457498 PMC3226273 · DOI
  32. Rabinovici GD Jagust WJ Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo Behav Neurol 2009 21 117 128 19847050 PMC2804478
  33. Kemppainen NM Aalto S Wilson IA Någren K Helin S Brück A Oikonen V Kailajärvi M Scheinin M Viitanen M Parkkola R Rinne JO PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology 2007 68 1603 1606 10.1212/01.wnl.0000260969.94695.56 17485647 · DOI
  34. Okello A Koivunen J Edison P Archer HA Turkheimer FE Någren K Bullock R Walker Z Kennedy A Fox NC Rossor MN Rinne JO Brooks DJ Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 2009 73 754 760 10.1212/WNL.0b013e3181b23564 19587325 PMC2830881 · DOI
  35. Wolk DA Price JC Saxton JA Snitz BE James JA Lopez OL Aizenstein HJ Cohen AD Weissfeld LA Mathis CA Klunk WE De-Kosky ST Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 2009 65 557 568 10.1002/ana.21598 19475670 PMC2828870 · DOI
  36. Jack CR Jr Wiste HJ Vemuri P Weigand SD Senjem ML Zeng G Bernstein MA Gunter JL Pankratz VS Aisen PS Weiner MW Petersen RC Shaw LM Trojanowski JQ Knopman DS Brain β-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 2010 133 3336 3348 10.1093/brain/awq277 20935035 PMC2965425 · DOI · Paper page
  37. Albert MS DeKosky ST Dickson D Dubois B Feldman HH Fox NC Gamst A Holtzman DM Jagust WJ Petersen RC Snyder PJ Carrillo MC Thies B Phelps CH The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 270 279 10.1016/j.jalz.2011.03.008 21514249 PMC3312027 · DOI · Paper page
  38. Rabinovici GD Rosen HJ Alkalay A Kornak J Furst AJ Agarwal N Mormino EC O'Neil JP Janabi M Karydas A Growdon ME Jang JY Huang EJ DeArmond SJ Trojanowski JQ Grinberg LT Gorno-Tempini ML Seeley WW Miller BL Jagust WJ Amyloid versus FDG PET in the differential diagnosis of AD and FTLD Neurology in press PMC3236517 22131541
  39. Braak E Griffing K Arai K Bohl J Bratzke H Braak H Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 1999 249 14 22 10654095
  40. Grimmer T Tholen S Yousefi BH Alexopoulos P Förschler A Förstl H Henriksen G Klunk WE Mathis CA Perneczky R Sorg C Kurz A Drzezga A Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease Biol Psychiatry 2010 68 879 884 10.1016/j.biopsych.2010.05.013 20598287 PMC3045041 · DOI
  41. Rabinovici GD Furst AJ Alkalay A Racine CA O'Neil JP Janabi M Baker SL Agarwal N Bonasera SJ Mormino EC Weiner MW Gorno-Tempini ML Rosen HJ Miller BL Jagust WJ Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden Brain 2010 133 512 528 10.1093/brain/awp326 20080878 PMC2858015 · DOI
  42. Furst AJ Rabinovici GD Rostomian AH Steed T Alkalay A Racine C Miller BL Jagust WJ Cognition, glucose metabolism and amyloid burden in Alzheimer's disease Neurobiol Aging 2010 in press PMC2920373 20417582
  43. Engler H Forsberg A Almkvist O Blomquist G Larsson E Savitcheva I Wall A Ringheim A Långström B Nordberg A Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 2006 129 2856 2866 10.1093/brain/awl178 16854944 · DOI
  44. Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 2009 132 1355 1365 10.1093/brain/awp062 19339253 PMC2677798 · DOI · Paper page
  45. Landt J D'Abrera JC Holland AJ Aigbirhio FI Fryer TD Canales R Hong YT Menon DK Baron JC Zaman SH Using positron emission tomography and carbon 11-labeled Pittsburgh Compound B to image brain fibrillar β-amyloid in adults with Down syndrome: safety, acceptability, and feasibility Arch Neurol 2011 68 890 896 10.1001/archneurol.2011.36 21403005 · DOI
  46. Rabinovici GD Jagust WJ Furst AJ Ogar JM Racine CA Mormino EC O'Neil JP Lal RA Dronkers NF Miller BL Gorno-Tempini ML Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia Ann Neurol 2008 64 388 401 10.1002/ana.21451 18991338 PMC2648510 · DOI · Paper page
  47. Leyton CE Villemagne VL Savage S Pike KE Ballard KJ Piguet O Burrell JR Rowe CC Hodges JR Subtypes of progressive aphasia: application of the international consensus criteria and validation using β-amyloid imaging Brain 2011 134 3030 3043 10.1093/brain/awr216 21908392 · DOI
  48. Formaglio M Costes N Seguin J Tholance Y Le Bars D Roullet-Solignac I Mercier B Krolak-Salmon P Vighetto A In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings J Neurol 2011 258 1841 1851 10.1007/s00415-011-6030-0 21479849 · DOI
  49. Rosenbloom MH Alkalay A Agarwal N Baker SL O'Neil JP Janabi M Yen IV Growdon M Jang J Madison C Mormino EC Rosen HJ Gorno-Tempini ML Weiner MW Miller BL Jagust WJ Rabinovici GD Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution Neurology 2011 76 1789 1796 10.1212/WNL.0b013e31821cccad 21525424 PMC3100124 · DOI
  50. de Souza LC Corlier F Habert MO Uspenskaya O Maroy R Lamari F Chupin M Lehéricy S Colliot O Hahn-Barma V Samri D Dubois B Bottlaender M Sarazin M Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease Brain 2011 134 2036 2043 10.1093/brain/awr130 21705422 · DOI
  51. Ng SY Villemagne VL Masters CL Rowe CC Evaluating atypical dementia syndromes using positron emission tomography with carbon 11-labeled Pittsburgh Compound B Arch Neurol 2007 64 1140 1144 10.1001/archneur.64.8.1140 17698704 · DOI
  52. McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly JJ Mayeux R Mohs RC Morris JC Rossor MN Scheltens P Carrillo MC Thies B Weintraub S Phelps CH The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250 PMC3312024 · DOI · Paper page
  53. Johnson KA Gregas M Becker JA Kinnecom C Salat DH Moran EK Smith EE Rosand J Rentz DM Klunk WE Mathis CA Price JC Dekosky ST Fischman AJ Greenberg SM Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann Neurol 2007 62 229 234 10.1002/ana.21164 17683091 · DOI · Paper page
  54. Maxwell SS Jackson CA Paternoster L Cordonnier C Thijs V Al-Shahi Salman R Sudlow CL Genetic associations with brain microbleeds: systematic review and meta-analyses Neurology 2011 77 158 167 10.1212/WNL.0b013e318224afa3 21715706 PMC3140069 · DOI
  55. Lee JH Kim SH Kim GH Seo SW Park HK Oh SJ Kim JS Cheong HK Na DL Identification of pure subcortical vascular dementia using 11C-Pittsburgh Compound B Neurology 2011 77 18 25 10.1212/WNL.0b013e318221acee 21593437 · DOI · Paper page
  56. Edison P Rowe CC Rinne JO Ng S Ahmed I Kemppainen N Villemagne VL O'Keefe G Någren K Chaudhury KR Masters CL Brooks DJ Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J Neurol Neurosurg Psychiatry 2008 79 1331 1338 10.1136/jnnp.2007.127878 18653550 · DOI
  57. Foster ER Campbell MC Burack MA Hartlein J Flores HP Cairns NJ Hershey T Perlmutter JS Amyloid imaging of Lewy body-associated disorders Mov Disord 2010 25 2516 2523 10.1002/mds.23393 20922808 PMC2978796 · DOI
  58. Gomperts SN Rentz DM Moran E Becker JA Locascio JJ Klunk WE Mathis CA Elmaleh DR Shoup T Fischman AJ Hyman BT Growdon JH Johnson KA Imaging amyloid deposition in Lewy body diseases Neurology 2008 71 903 910 10.1212/01.wnl.0000326146.60732.d6 18794492 PMC2637553 · DOI · Paper page
  59. Maetzler W Liepelt I Reimold M Reischl G Solbach C Becker C Schulte C Leyhe T Keller S Melms A Gasser T Berg D Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiol Dis 2009 34 107 112 10.1016/j.nbd.2008.12.008 19162186 · DOI
  60. Rowe CC Ng S Ackermann U Gong SJ Pike K Savage G Cowie TF Dickinson KL Maruff P Darby D Smith C Woodward M Merory J Tochon-Danguy H O'Keefe G Klunk WE Mathis CA Price JC Masters CL Villemagne VL Imaging β-amyloid burden in aging and dementia Neurology 2007 68 1718 1725 10.1212/01.wnl.0000261919.22630.ea 17502554 · DOI · Paper page
  61. Claassen DO Lowe VJ Peller PJ Petersen RC Josephs KA Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy Parkinsonism Relat Disord 2011 17 160 165 10.1016/j.parkreldis.2010.12.006 21195652 · DOI
  62. Rabinovici GD Miller BL Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management CNS Drugs 2010 24 375 398 10.2165/11533100-000000000-00000 20369906 PMC2916644 · DOI
  63. Gorno-Tempini ML Hillis AE Weintraub S Kertesz A Mendez M Cappa SF Ogar JM Rohrer JD Black S Boeve BF Manes F Dronkers NF Vandenberghe R Rascovsky K Patterson K Miller BL Knopman DS Hodges JR Mesulam MM Grossman M Classification of primary progressive aphasia and its variants Neurology 2011 76 1006 1014 10.1212/WNL.0b013e31821103e6 21325651 PMC3059138 · DOI · Paper page
  64. Neary D Snowden JS Gustafson L Passant U Stuss D Black S Freedman M Kertesz A Robert PH Albert M Boone K Miller BL Cummings J Benson DF Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria Neurology 1998 51 1546 1554 9855500
  65. Mackenzie IR Neumann M Bigio EH Cairns NJ Alafuzoff I Kril J Kovacs GG Ghetti B Halliday G Holm IE Ince PG Kamphorst W Revesz T Rozemuller AJ Kumar-Singh S Akiyama H Baborie A Spina S Dickson DW Trojanowski JQ Mann DM Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update Acta Neuropathol 2010 119 1 4 10.1007/s00401-009-0612-2 19924424 PMC2799633 · DOI · Paper page
  66. Ratnavalli E Brayne C Dawson K Hodges JR The prevalence of frontotemporal dementia Neurology 2002 58 1615 1621 12058088
  67. Rabinovici GD Furst AJ O'Neil JP Racine CA Mormino EC Baker SL Chetty S Patel P Pagliaro TA Klunk WE Mathis CA Rosen HJ Miller BL Jagust WJ 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration Neurology 2007 68 1205 1212 10.1212/01.wnl.0000259035.98480.ed 17420404 · DOI
  68. Lee SE Rabinovici GD Mayo MC Clinicopathological correlations in corticobasal degeneration Ann Neurol 2011 70 327 340 10.1002/ana.22424 21823158 PMC3154081 · DOI · Paper page
  69. Hamilton R Patel S Lee EB Jackson EM Lopinto J Arnold SE Clark CM Basil A Shaw LM Xie SX Grady MS Trojanowski JQ Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology Ann Neurol 2010 68 535 540 10.1002/ana.22015 20687117 PMC2964442 · DOI
  70. Silverberg GD Mayo M Saul T Rubenstein E McGuire D Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis Lancet Neurol 2003 2 506 511 10.1016/S1474-4422(03)00487-3 12878439 · DOI
  71. Hyare H Ramlackhansingh A Gelosa G Edison P Rudge P Brandner S Brooks DJ Collinge J Mead S 11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease J Neurol Neurosurg Psychiatry 2011 in press 21478204
  72. Boxer AL Rabinovici GD Kepe V Goldman J Furst AJ Huang SC Baker SL O'neil JP Chui H Geschwind MD Small GW Barrio JR Jagust W Miller BL Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease Neurology 2007 69 283 290 10.1212/01.wnl.0000265815.38958.b6 17636066 · DOI
  73. Geschwind MD Shu H Haman A Sejvar JJ Miller BL Rapidly progressive dementia Ann Neurol 2008 64 97 108 10.1002/ana.21430 18668637 PMC2647859 · DOI
  74. Ances BM Benzinger TL Christensen JJ Thomas J Venkat R Teshome M Aldea P Fagan AM Holtzman DM Morris JC HIV associated neurocognitive disorder (HAND) is not associated with increased fibrillar amyloid deposits using 11C-PiB in middle-aged HIV+ participants Arch Neurol in press PMC3536500 22232345
  75. Savva GM Wharton SB Ince PG Forster G Matthews FE Brayne C Age, neuropathology, and dementia N Engl J Med 2009 360 2302 2309 10.1056/NEJMoa0806142 19474427 · DOI · Paper page
  76. Li Y Rinne JO Mosconi L Pirraglia E Rusinek H DeSanti S Kemppainen N Någren K Kim BC Tsui W de Leon MJ Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease Eur J Nucl Med Mol Imaging 2008 35 2169 2181 10.1007/s00259-008-0833-y 18566819 PMC2693402 · DOI · Paper page
  77. Devanand DP Mikhno A Pelton GH Cuasay K Pradhaban G Dileep Kumar JS Upton N Lai R Gunn RN Libri V Liu X van Heertum R Mann JJ Parsey RV Pittsburgh Compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls J Geriatr Psychiatry Neurol 2010 23 185 198 10.1177/0891988710363715 20430977 PMC3110668 · DOI
  78. Jagust WJ Landau SM Shaw LM Trojanowski JQ Koeppe RA Reiman EM Foster NL Petersen RC Weiner MW Price JC Mathis CA Relationships between biomarkers in aging and dementia Neurology 2009 73 1193 1199 10.1212/WNL.0b013e3181bc010c 19822868 PMC2764726 · DOI · Paper page
  79. Cairns NJ Ikonomovic MD Benzinger T Storandt M Fagan AM Shah AR Reinwald LT Carter D Felton A Holtzman DM Mintun MA Klunk WE Morris JC Absence of PIttsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease Arch Neurol 2009 66 1557 1562 10.1001/archneurol.2009.279 20008664 PMC2796200 · DOI
  80. Burke JF Albin RL Koeppe RA Giordani B Kilbourn MR Gilman S Frey KA Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography Brain 2011 134 1647 1657 10.1093/brain/awr089 21555336 PMC3102241 · DOI
  81. Petersen RC Thomas RG Grundman M Bennett D Doody R Ferris S Galasko D Jin S Kaye J Levey A Pfeiffer E Sano M van Dyck CH Thal LJ Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 2005 352 2379 2388 10.1056/NEJMoa050151 15829527 · DOI · Paper page
  82. van Rossum IA Vos S Handels R Visser PJ Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design J Alzheimers Dis 2010 20 881 891 20413876

Cited by

Sorted by citations

Authors
Laforce, R., & Rabinovici, G. D.
Affiliations
University of California, San Francisco (US)
Corresponding author
Laforce, Robert
ORCID
Venue
Alzheimer's Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2011-11-10
Volume
3
Issue
6
Pages
31-31
ISSN
1758-9193 (ISSN-L)
DOI
10.1186/alzrt93
PMC
PMC3308020
OpenAlex
W2166939267
Cited by
79
References
14
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 9 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 8
FWCI
5.28
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Alzheimer s Research & Therapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • John Douglas French Alzheimer's Foundation
  • National Institute on Aging (K23AG031861)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
amyloid PET, Pittsburgh compound B, Alzheimer's disease, differential diagnosis of dementia, frontotemporal lobar degeneration, mild cognitive impairment, amyloid plaques, early-onset Alzheimer's disease, asymptomatic screening, positive predictive value, neurodegenerative diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review